High-Dose Ibuprofen Therapy for Patent Ductus Arteriosus in Extremely Preterm Neonates: Do We Have a Final Answer?

2012 ◽  
Vol 92 (5) ◽  
pp. 557-557 ◽  
Author(s):  
S Sajan Saini ◽  
V Mahajan
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
A. Warnock ◽  
L. Szatkowski ◽  
A. Lakshmanan ◽  
L. Lee ◽  
W. Kelsall

Abstract Background This study aimed to provide UK data describing the incidence of patent ductus arteriosus (PDA) surgery in the neonatal population, including: pre-ligation management, and outcomes until discharge. We used British Paediatric Surveillance Unit (BPSU) methodology; collecting data via questionnaires for preterm neonates undergoing PDA ligation (PDAL) between 1st Sept 2012 – 30th Sept 2013. Infants born less than 37 weeks gestation, who underwent PDAL prior to discharge home, with no other structural cardiac abnormality, were included. Information collected included: patient demographics, pre and post-operative clinical characteristics, pre-operative medical management, post-operative complications and outcome. Results Over the study, 263 infants underwent PDAL an incidence of 3.07 per 10,000 live births. 88% were born extremely preterm (< 28 weeks) and 60% were male. The commonest reasons for ligation were inability to wean respiratory support (83.7%) and haemodynamically significant PDA (87.8%). Pre-operatively 65.7% received medical therapy. Surgery was performed at a median age of 33 days (range 9-260, IQR 24-48); the corrected age was less than 31 + 6 week in 50.6% babies at PDAL. Most, (90%), of procedures were open ligation; only 9 (3.4%) were catheter occlusions (PDACO). 20.5% of patients had post-operative complications. The 30-day mortality was 3%, with 93.5% surviving to hospital discharge. Conclusion This study showed there was little consensus over medical and surgical management of the PDA or timing of surgery.


Sign in / Sign up

Export Citation Format

Share Document